SpringWorks Therapeutics Inc Stock

$32.28

0.03% yesterday

Nasdaq, Sep 27, 10:01 pm CET

ISIN

US85205L1070

Symbol

SWTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

SpringWorks Therapeutics Inc Stock price

$32.28

+12.96 67.08% 5Y

Nasdaq, Closing price Fri, Sep 27 2024

-0.01 0.03%

ISIN

US85205L1070

Symbol

SWTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$2.40b
Enterprise Value	$2.02b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	23.44
P/S ratio (TTM) P/S ratio	27.82
P/B ratio (TTM) P/B ratio	4.31
Revenue (TTM) Revenue	$86.19m
EBIT (operating result TTM) EBIT	$-321.31m
Free Cash Flow (TTM) Free Cash Flow	$-236.76m
Cash position	$383.89m
EPS (TTM) EPS	$-4.28
P/E forward	negative
P/S forward	12.28
EV/Sales forward	10.35
Short interest	22.33%

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Get Started for Free Today

SpringWorks Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a SpringWorks Therapeutics Inc forecast:

8x Buy

100%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a SpringWorks Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from SpringWorks Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	86 86	- 100%
- Direct Costs	7.12 7.12	195% 195% 8%
Gross Profit	79 79	3,381% 3,381% 92%
- Selling and Administrative Expenses	218 218	34% 34% 253%
- Research and Development Expense	179 179	25% 25% 208%
EBITDA	-318 -318	3% 3% -369%
- Depreciation and Amortization	3.04 3.04	26% 26% 4%
EBIT (Operating Income) EBIT	-321 -321	3% 3% -373%
Net Profit	-301 -301	1% 1% -349%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

SpringWorks Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

about one month ago

FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

– PDUFA target action date of February 28, 2025 – – EU Marketing Authorization Application also validated by European Medicines Agency – STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has acce...

Negative

Seeking Alpha

●

about 2 months ago

SpringWorks Therapeutics Recent Developments Move This To Speculative Buy (Upgrade)

Investment merits have increased materially since my last article with more support for its approved therapy and pipeline advancements. Ample liquidity supports its operations and pipeline development. Despite its potential SpringWorks carries significant risks for investors.

Positive

Seeking Alpha

●

about 2 months ago

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

SWTX's market confidence has increased post-launch, with $40.2 million in product revenue and $19.5 million in collaboration revenue in the first quarter. Nirogacestat approval for desmoid tumors and potential approval for mirdametinib in 2025 position SWTX well for growth. SWTX's strong commercial execution and expanding product portfolio indicate the potential for profitability and market app...

More SpringWorks Therapeutics Inc News

Company Profile

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. It focuses on developing drugs for underserved patient populations suffering from devastating rare diseases and cancer. Its pipeline include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

Head office	United States
CEO	Saqib Islam
Employees	305
Founded	2017
Website	www.springworkstx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now